American Century Companies Inc. Trims Stock Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• American Century Companies Inc. reduced its stake in Thermo Fisher Scientific Inc. by 5.5%, now holding 103,778 shares worth approximately $51.64 million.
• Various institutional investors, including Vanguard Group Inc. and T. Rowe Price Investment Management Inc., have increased their holdings in Thermo Fisher during the same quarter.
• The company's quarterly earnings reported $5.36 EPS, exceeding analysts' expectations with revenue of $10.86 billion, marking a 2.9% increase from the previous year.

American Century Companies Inc. lowered its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 5.5% in the first quarter, according to its most recent 13F filing with the SEC. The fund owned 103,778 shares of the medical research company's stock after selling 6,028 shares during the period. American Century Companies Inc.'s holdings in Thermo Fisher Scientific were worth $51,640,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Vanguard Group Inc. raised its holdings in Thermo Fisher Scientific by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 33,479,957 shares of the medical research company's stock worth $16,659,627,000 after purchasing an additional 230,382 shares during the period. Northern Trust Corp raised its holdings in Thermo Fisher Scientific by 13.2% in the 4th quarter. Northern Trust Corp now owns 3,910,015 shares of the medical research company's stock worth $2,034,107,000 after purchasing an additional 455,004 shares during the period. T. Rowe Price Investment Management Inc. raised its holdings in Thermo Fisher Scientific by 86.9% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,083,900 shares of the medical research company's stock worth $1,604,338,000 after purchasing an additional 1,433,444 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in Thermo Fisher Scientific by 4.1% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,925,591 shares of the medical research company's stock worth $1,455,774,000 after purchasing an additional 115,463 shares during the period. Finally, Pictet Asset Management Holding SA raised its holdings in Thermo Fisher Scientific by 7.2% in the 1st quarter. Pictet Asset Management Holding SA now owns 2,879,274 shares of the medical research company's stock worth $1,432,816,000 after purchasing an additional 193,378 shares during the period. Hedge funds and other institutional investors own 89.23% of the company's stock.

Insider Buying and Selling

In related news, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the transaction, the executive vice president directly owned 22,367 shares in the company, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $451.82, for a total value of $4,518,200.00. Following the completion of the transaction, the chief executive officer owned 115,174 shares in the company, valued at $52,037,916.68. This represents a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 18,400 shares of company stock worth $8,345,792 over the last quarter. 0.33% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on TMO. Royal Bank Of Canada reduced their price target on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. HSBC reiterated a "hold" rating and set a $510.00 price objective on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Evercore ISI cut their price objective on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a research note on Tuesday, July 8th. Raymond James Financial reiterated an "outperform" rating and set a $535.00 price objective (up from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Finally, William Blair started coverage on Thermo Fisher Scientific in a research note on Monday. They set an "outperform" rating for the company. Sixteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $593.00.

Thermo Fisher Scientific Price Performance

TMO stock opened at $497.9350 on Wednesday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The business has a 50 day simple moving average of $438.09 and a 200-day simple moving average of $458.53. The firm has a market capitalization of $188.03 billion, a PE ratio of 28.80, a price-to-earnings-growth ratio of 2.60 and a beta of 0.74. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. The business had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business's revenue was up 2.9% compared to the same quarter last year. During the same period in the prior year, the business earned $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be given a $0.43 dividend. The ex-dividend date is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio is 9.95%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.